Evidence map›Paper›PMID 41198237›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Preclinical Validation of [

Anja C L Mortensen, Tabassom Mohajershojai, Amanda Gustafsson, Hanna Berglund, Ram Kumar Selvaraju, Camilla Hofström, Helena Persson, Mats Ohlin, Thuy A Tran, Anton Forsberg Morén and 5 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  2. Review
  3. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anja C L MortensenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; anja.lundgren.mortensen@ki.se.
Tabassom MohajershojaiDepartment of Medicine, Karolinska Institutet, Stockholm, Sweden.
Amanda GustafssonDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Hanna BerglundDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Ram Kumar SelvarajuPreclinical PET-MRI Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Camilla HofströmDrug Discovery and Development, Science for Life Laboratories and Royal Institute of Technology, Stockholm, Sweden.
Helena PerssonDrug Discovery and Development, Science for Life Laboratories and Royal Institute of Technology, Stockholm, Sweden.
Mats OhlinDrug Discovery and Development, Science for Life Laboratories and Department of Immunotechnology, Lund University, Lund, Sweden.
Thuy A TranDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Anton Forsberg MorénDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Piotr OchniewiczDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Jan ZedeniusDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Peter BernhardtDepartment of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; and.
Fredrik Y FrejdDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.
Marika NestorDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratories, Uppsala University, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted radionuclide therapy is an emerging potent therapeutic strategy in oncology. The cell surface antigen CD44v6 is a potential pan-cancer target for radionuclide therapy. This study aimed to evaluate the therapeutic efficacy, biodistribution, dosimetry, and safety profile of AKIR001, an antibody targeting CD44v6 labeled with

Indexed as

Antibodies, MonoclonalHyaluronan ReceptorsLutetiumRadioisotopesAnimalsCell Line, TumorFemaleHumansMacaca fascicularisMicePositron-Emission TomographyRabbitsRadiometryRadiopharmaceuticalsTissue DistributionXenograft Model Antitumor AssaysAntibodies, MonoclonalCD44v6 antigenHyaluronan ReceptorsLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsCD44v6rADCsradioantibody–drug conjugatesRPTtranslational oncology

Identifiers

PMID41198237
PMCPMC12866357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.